Literature DB >> 27098816

Current Approach to the Diagnosis and Management of Portopulmonary Hypertension.

Lynn A Fussner1, Michael J Krowka2,3.   

Abstract

Portopulmonary hypertension (POPH) is a form of pulmonary arterial hypertension occurring in the setting of portal hypertension with or without hepatic cirrhosis. The presence of both portal and pulmonary vascular disease contributes to complicated hemodynamics and therapeutic challenges, though the severities do not appear to correlate directly. Diagnosis of POPH, and distinction from the commonly observed hyperdynamic state of end-stage liver disease, is typically accomplished with an initial screening transthoracic echocardiogram, followed by right heart catheterization for confirmation of hemodynamic parameters. Though few studies have directly evaluated use in POPH, pulmonary artery-directed therapy is the cornerstone of management, along with consideration of liver transplantation. Perioperative and long-term outcomes are variable, but uniformly worse in the setting of uncontrolled pulmonary pressures. Risk stratification and optimal patient selection for these interventions are areas of ongoing investigation.

Entities:  

Keywords:  Echocardiography; Liver transplant; Portopulmonary hypertension; Pulmonary arterial hypertension; Right heart catheterization; Vasodilator

Mesh:

Substances:

Year:  2016        PMID: 27098816     DOI: 10.1007/s11894-016-0504-2

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  85 in total

Review 1.  Pulmonary-Hepatic vascular Disorders (PHD).

Authors:  R Rodríguez-Roisin; M J Krowka; Ph Hervé; M B Fallon
Journal:  Eur Respir J       Date:  2004-11       Impact factor: 16.671

2.  Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.

Authors:  S D Lee; K R Shroyer; N E Markham; C D Cool; N F Voelkel; R M Tuder
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

3.  Riociguat for the treatment of pulmonary arterial hypertension.

Authors:  Hossein-Ardeschir Ghofrani; Nazzareno Galiè; Friedrich Grimminger; Ekkehard Grünig; Marc Humbert; Zhi-Cheng Jing; Anne M Keogh; David Langleben; Michael Ochan Kilama; Arno Fritsch; Dieter Neuser; Lewis J Rubin
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

4.  Hepatic localization of endothelin-1 in patients with idiopathic portal hypertension and cirrhosis of the liver.

Authors:  P S Kamath; H A Carpenter; R V Lloyd; M A McKusick; J L Steers; D M Nagorney; V M Miller
Journal:  Liver Transpl       Date:  2000-09       Impact factor: 5.799

5.  Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension.

Authors:  M J Krowka; R P Frantz; M D McGoon; C Severson; D J Plevak; R H Wiesner
Journal:  Hepatology       Date:  1999-09       Impact factor: 17.425

6.  Coexistent pulmonary and portal hypertension: morphologic and clinical features.

Authors:  B S Edwards; E K Weir; W D Edwards; J Ludwig; R K Dykoski; J E Edwards
Journal:  J Am Coll Cardiol       Date:  1987-12       Impact factor: 24.094

7.  Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database.

Authors:  Michael J Krowka; M Susan Mandell; Michael A E Ramsay; Steve M Kawut; Michael B Fallon; Cosme Manzarbeitia; Manuel Pardo; Paul Marotta; Shinji Uemoto; Markus P Stoffel; Joanne T Benson
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

8.  Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension.

Authors:  Michael S Gough; R James White
Journal:  Liver Transpl       Date:  2009-01       Impact factor: 5.799

9.  Early initiation of prostacyclin in portopulmonary hypertension: 10 years of a transplant center's experience.

Authors:  Rana L A Awdish; Hector R Cajigas
Journal:  Lung       Date:  2013-08-25       Impact factor: 2.584

Review 10.  Prostacyclin and its analogues in the treatment of pulmonary hypertension.

Authors:  Horst Olschewski; Frank Rose; Ralph Schermuly; H Ardeschir Ghofrani; Beate Enke; Andrea Olschewski; Werner Seeger
Journal:  Pharmacol Ther       Date:  2004-05       Impact factor: 12.310

View more
  4 in total

Review 1.  Review article: Update on current and emergent data on hepatopulmonary syndrome.

Authors:  Stergios Soulaidopoulos; Evangelos Cholongitas; George Giannakoulas; Maria Vlachou; Ioannis Goulis
Journal:  World J Gastroenterol       Date:  2018-03-28       Impact factor: 5.742

2.  Refractory ascites-the contemporary view on pathogenesis and therapy.

Authors:  Beata Kasztelan-Szczerbinska; Halina Cichoz-Lach
Journal:  PeerJ       Date:  2019-10-15       Impact factor: 2.984

Review 3.  Pulmonary manifestations of chronic liver disease: a comprehensive review.

Authors:  Stergios Soulaidopoulos; Ioannis Goulis; Evangelos Cholongitas
Journal:  Ann Gastroenterol       Date:  2020-03-27

4.  Clinical Characteristics of Systemic Lupus Erythematosus with Cirrhosis.

Authors:  Hanxiao You; Linyi Peng; Jiuliang Zhao; Yunyun Fei; Qian Wang; Wen Zhang; Mengtao Li; Xiaofeng Zeng
Journal:  J Immunol Res       Date:  2020-05-21       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.